Targeting the "fuel injector" of neovascularization (tyrosine kinase) appears to make sense. There is some initial anatomic validation to tyrosine kinase inhibition, but the devil lies in the details. Whether this route is the answer that will help change the way we treat retinal disease in the future is yet to be determined.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Jul 1 2010|
ASJC Scopus subject areas